These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2004-004456-39 A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Ca... 2012-06-01 bad-data
Ongoing 2006-004328-35 Etude de phase II de l'association CISPLATINE TOPOTECAN et CETUXIMAB chez les patientes atteintes d'un cancer épithelial du col de l'uterus avancé ou en rechute. not-yet-due
Completed, report not yet due 2006-004332-79 "Essai multicentrique de phase II randomisé évaluant la tolérance et l'efficacité du tamoxifène seul versus association Tamoxifène-RAD001 (Everolimus), chez les patientes atteintes de cancer du sein m... 2018-09-12 not-yet-due
Ongoing, reported early 2007-002736-28 A multicentre study DOGMES: Liposomal doxorubicin in geriatric oncology - Metastatic breast cancer - first line treatment by pegylated liposomal doxorubicin in patients of more than 70 years old with ... not-yet-due
Ongoing 2007-003002-10 A multicentre phase II study, estimating the efficiency and the tolerance of RAD001 (Everolimus) , in patients with endometrial metastatic cancer resistant to a first line of chemotherapy not-yet-due
Exempt 2008-001842-19 Etude de phase I / II de l’association carboplatine et topotecan oral hebdomadaire chez des patientes atteintes de cancer du col de l’utérus métastatique ou en rechute. not-yet-due
Not reported 2008-007497-37 ESSAI EN DEUX ETAPES DE L’EVALUATION DE LA LENALIDOMIDE (REVLIMID®) DANS LE CANCER DE L’OVAIRE EN RECHUTE TARDIVE (> 6 MOIS): - EN MONOTHERAPIE CHEZ DES PATIENTES ASYMPTOMATIQUES AVEC UNE ELEVATION D... 2016-07-21 due-trials
Completed, report not yet due 2009-016338-29 Essai randomisé multicentrique de phase III comparant la poursuite du traitement d’entretien par l’association bevacizumab + taxane versus remplacement par bevacizumab + exemestane chez des patientes ... 2018-09-18 not-yet-due
Not reported 2009-016708-21 Essai multicentrique de phase II évaluant l'efficcacité et la tolérance de l'association de bevacizumab, paclitaxel et capecitabine en première ligne chez des patientes atteintes de cancer du sein mé... 2016-02-03 due-trials
Completed, but no date 2011-002576-16 Phase 2 multicenter study to assess the safety and efficacy of BKM120 as monotherapy in the treatment of initial or recurrent metastatic endometrial cancer after first line therapy in patients who can... bad-data
Ongoing 2011-006288-23 Randomized double blind placebo-controlled phase II trial of Vargatef® in addition to first line chemotherapy with interval debulking surgery in patients with adenocarcinoma of the ovary, the fallopia... not-yet-due
Ongoing 2012-002841-39 A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with relapse... not-yet-due
Ongoing 2013-001710-15 Phase II study in patient in first line for HER - metastasis breast cancer treated with eribulin and bevacizumab not-yet-due
Ongoing 2014-004027-52 Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated... not-yet-due
Ongoing 2015-005471-24 A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemoth... not-yet-due
Ongoing 2016-004163-39 A randomized, open-label, multicentric phase II trial of PEMBROLIZUMAB (Ketruda®) with chemotherapy versus chemotherapy alone (standard of care) as neo adjuvant treatment of ovarian cancer not amenabl... not-yet-due